The Central Laboratory, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Department of Spleen and Stomach Diseases, Yantai Hospital of Traditional Chinese Medicine, Yantai, Shandong, China.
Mediators Inflamm. 2020 Apr 9;2020:5934821. doi: 10.1155/2020/5934821. eCollection 2020.
The high mortality of colorectal cancer (CRC) patients and the limitations of conventional tumor-node-metastasis (TNM) stage emphasized the necessity of exploring hub genes closely related to carcinogenesis and prognosis in CRC. The study is aimed at identifying hub genes associated with carcinogenesis and prognosis for CRC. We identified and validated 212 differentially expressed genes (DEGs) from six Gene Expression Omnibus (GEO) datasets and the Cancer Genome Atlas (TCGA) database. We investigated functional enrichment analysis for DEGs. The protein-protein interaction (PPI) network was constructed, and hub modules and genes in CRC carcinogenesis were extracted. A prognostic signature was developed and validated based on Cox proportional hazards regression analysis. The DEGs mainly regulated biological processes covering response to stimulus, metabolic process, and affected molecular functions containing protein binding and catalytic activity. The DEGs played important roles in CRC-related pathways involving in preneoplastic lesions, carcinogenesis, metastasis, and poor prognosis. Hub genes closely related to CRC carcinogenesis were extracted including six genes in model 1 (CXCL1, CXCL3, CXCL8, CXCL11, NMU, and PPBP) and two genes and Metallothioneins (MTs) in model 2 (SLC26A3 and SLC30A10). Among them, CXCL8 was also related to prognosis. An eight-gene signature was proposed comprising AMH, WBSCR28, SFTA2, MYH2, POU4F1, SIX4, PGPEP1L, and PAX5. The study identified hub genes in CRC carcinogenesis and proposed an eight-gene signature with good reproducibility and robustness at the molecular level for CRC, which might provide directive significance for treatment selection and survival prediction.
结直肠癌(CRC)患者的高死亡率和传统的肿瘤-淋巴结-转移(TNM)分期的局限性强调了探索与CRC 发生和预后密切相关的关键基因的必要性。本研究旨在鉴定与 CRC 发生和预后相关的关键基因。我们从六个基因表达综合(GEO)数据集和癌症基因组图谱(TCGA)数据库中鉴定和验证了 212 个差异表达基因(DEG)。我们研究了 DEG 的功能富集分析。构建了蛋白质-蛋白质相互作用(PPI)网络,并提取了 CRC 发生的关键模块和基因。基于 Cox 比例风险回归分析开发和验证了预后标志。DEG 主要调节涵盖对刺激的反应、代谢过程等生物过程,以及影响蛋白结合和催化活性等分子功能。DEG 在涉及癌前病变、癌变、转移和预后不良的 CRC 相关途径中发挥重要作用。提取了与 CRC 发生密切相关的关键基因,包括模型 1 中的 6 个基因(CXCL1、CXCL3、CXCL8、CXCL11、NMU 和 PPBP)和模型 2 中的 2 个基因和金属硫蛋白(MTs)(SLC26A3 和 SLC30A10)。其中,CXCL8 也与预后相关。提出了一个由 8 个基因组成的特征,包括 AMH、WBSCR28、SFTA2、MYH2、POU4F1、SIX4、PGPEP1L 和 PAX5。本研究鉴定了 CRC 发生中的关键基因,并提出了一个具有良好可重复性和稳健性的 8 基因特征,为 CRC 的分子水平治疗选择和生存预测提供了指导意义。